159 related articles for article (PubMed ID: 9484402)
21. [Lhermitte's sign in three oncological patients].
Porta-Etessam J; Martínez-Salio A; Berbel A; Balsalobre-Aznar J; Esteban J; Benito-León J; Ruiz J
Rev Neurol; 2000 Apr 1-15; 30(7):649-51. PubMed ID: 10859744
[TBL] [Abstract][Full Text] [Related]
22. A phase II study of single-agent docetaxel chemotherapy for non-small cell lung cancer.
Perng RP; Shih JF; Chen YM; Chou KC; Lee YC; Tsai CM
Jpn J Clin Oncol; 2000 Oct; 30(10):429-34. PubMed ID: 11185888
[TBL] [Abstract][Full Text] [Related]
23. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control.
Varveris H; Delakas D; Anezinis P; Haldeopoulos D; Mazonakis M; Damilakis J; Metaxaris G; Chondros N; Mavromanolakis E; Daskalopoulos G; Dimitrakopoulos A; Kranidis A
Anticancer Res; 1997; 17(6D):4771-80. PubMed ID: 9494605
[TBL] [Abstract][Full Text] [Related]
24. The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication.
Béhar A; Pujade-Lauraine E; Maurel A; Brun MD; Chauvin FF; Feuilhade de Chauvin F; Oulid-Aissa D; Hille D
Br J Clin Pharmacol; 1997 Jun; 43(6):653-8. PubMed ID: 9205828
[TBL] [Abstract][Full Text] [Related]
25. The development of Lhermitte's sign during cisplatin chemotherapy. Possible drug-induced toxicity causing spinal cord demyelination.
Walther PJ; Rossitch E; Bullard DE
Cancer; 1987 Nov; 60(9):2170-2. PubMed ID: 3440227
[TBL] [Abstract][Full Text] [Related]
26. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.
Chan S; Friedrichs K; Noel D; Pintér T; Van Belle S; Vorobiof D; Duarte R; Gil Gil M; Bodrogi I; Murray E; Yelle L; von Minckwitz G; Korec S; Simmonds P; Buzzi F; González Mancha R; Richardson G; Walpole E; Ronzoni M; Murawsky M; Alakl M; Riva A; Crown J;
J Clin Oncol; 1999 Aug; 17(8):2341-54. PubMed ID: 10561296
[TBL] [Abstract][Full Text] [Related]
27. Phase I trial of Taxotere: five-day schedule.
Pazdur R; Newman RA; Newman BM; Fuentes A; Benvenuto J; Bready B; Moore D; Jaiyesimi I; Vreeland F; Bayssas MM
J Natl Cancer Inst; 1992 Dec; 84(23):1781-8. PubMed ID: 1359154
[TBL] [Abstract][Full Text] [Related]
28. Combination docetaxel/vinorelbine for metastatic breast cancer and non-small-cell lung cancer.
Aapro MS
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):46-9. PubMed ID: 9364543
[TBL] [Abstract][Full Text] [Related]
29. Lhermitte's sign as a presenting symptom of primary spinal cord tumor.
Newton HB; Rea GL
J Neurooncol; 1996 Aug; 29(2):183-8. PubMed ID: 8858524
[TBL] [Abstract][Full Text] [Related]
30. Docetaxel: standard recommended dose of 100 mg/m(2) is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy-A phase II single-center study.
Salminen E; Bergman M; Huhtala S; Ekholm E
J Clin Oncol; 1999 Apr; 17(4):1127. PubMed ID: 10561170
[TBL] [Abstract][Full Text] [Related]
31. Osteonecrosis of the jaws associated with cancer chemotherapy.
Wang J; Goodger NM; Pogrel MA
J Oral Maxillofac Surg; 2003 Sep; 61(9):1104-7. PubMed ID: 12966490
[No Abstract] [Full Text] [Related]
32. Phase II dose escalation: a novel approach to balancing efficacy and toxicity of anticancer agents. Japanese Docetaxel Ovarian Cancer Study Group.
Fujiwara K; Kohno I; Tanaka K; Ogita S; Sasaki Y; Hirabayashi K; Yakushiji M; Tsunematsu R; Terashima Y; Taguchi T; Ohashi Y; Noda K
Anticancer Res; 1999; 19(1B):639-44. PubMed ID: 10216469
[TBL] [Abstract][Full Text] [Related]
33. Weekly schedules of docetaxel.
Burris H
Semin Oncol; 1998 Dec; 25(6 Suppl 13):21-3. PubMed ID: 9865688
[TBL] [Abstract][Full Text] [Related]
34. Phase I study of docetaxel administered by bi-weekly infusion to patients with metastatic breast cancer.
Shin E; Ishitobi M; Hiraoia M; Kazumasa F; Hideyuki M; Nishisho I; Toshiro S; Yasunori H; Tosimasa T
Anticancer Res; 2000; 20(6C):4721-6. PubMed ID: 11205207
[TBL] [Abstract][Full Text] [Related]
35. Docetaxel-induced radiation recall dermatitis and successful rechallenge without recurrence.
Camidge DR; Kunkler IH
Clin Oncol (R Coll Radiol); 2000; 12(4):272-3. PubMed ID: 11005698
[No Abstract] [Full Text] [Related]
36. Coping with toxicities of docetaxel (Taxotere).
Schrijvers D; Wanders J; Dirix L; Prove A; Vonck I; van Oosterom A; Kaye S
Ann Oncol; 1993 Aug; 4(7):610-1. PubMed ID: 8103352
[TBL] [Abstract][Full Text] [Related]
37. Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity.
Adjei AA; Klein CE; Kastrissios H; Goldberg RM; Alberts SR; Pitot HC; Sloan JA; Reid JM; Hanson LJ; Atherton P; Rubin J; Erlichman C
J Clin Oncol; 2000 Mar; 18(5):1116-23. PubMed ID: 10694565
[TBL] [Abstract][Full Text] [Related]
38. Nonneutropenic febrile episodes associated with docetaxel-based chemotherapy in patients with solid tumors.
Souglakos J; Kotsakis A; Kouroussis C; Kakolyris S; Mavroudis D; Kalbakis K; Agelaki S; Vlachonikolis J; Georgoulias V; Samonis G
Cancer; 2002 Sep; 95(6):1326-33. PubMed ID: 12216102
[TBL] [Abstract][Full Text] [Related]
39. Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group Study.
Sternberg CN; ten Bokkel Huinink WW; Smyth JF; Bruntsch V; Dirix LY; Pavlidis NA; Franklin H; Wanders S; Le Bail N; Kaye SB
Br J Cancer; 1994 Aug; 70(2):376-9. PubMed ID: 7914427
[TBL] [Abstract][Full Text] [Related]
40. Phase I study of docetaxel with concomitant thoracic radiation therapy.
Mauer AM; Masters GA; Haraf DJ; Hoffman PC; Watson SM; Golomb HM; Vokes EE
J Clin Oncol; 1998 Jan; 16(1):159-64. PubMed ID: 9440738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
